Atlas Trials

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Clinical trial NCT06232902 · COMPLETED

Trial details

NCT number
NCT06232902
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Tumor
Start date
2024-06-20
Primary completion
2024-11-18
Enrollment
84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.